UNSPSC 51422357: Methylprednisolone suleptanate

This classification denotes a therapeutic glucocorticoid with the molecular formula C33H48NO10S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G6CS53NCVS, chemically known as 7-(methyl(2-sulfoethyl)carbamoyl)heptanoic acid, c-21-ester with 11beta,17,21-trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione, monosodium salt but more generally known as methylprednisolone suleptanate, which bears US NIH Compound Identifier 56067.

UNSPSC 51422357 Methylprednisolone suleptanate is a Commodity code that in practice spans pharmaceutical procurement by state and local health agencies, though the recent opportunities posted under it show significant category misalignment — the Seminole County, Florida solicitation targets naloxone and drug deactivation systems rather than the corticosteroid named in the code, and the Texas Health and Human Services Commission RFI addresses direct-to-manufacturer prescription fulfillment architecture without specifying drug classes. State health departments and county health agencies are the primary issuing bodies under this code based on recent activity. The scope of work actual buyers are pursuing includes acquisition of emergency response pharmaceuticals (naloxone in particular), drug deactivation and disposal systems, and broader pharmacy benefit program infrastructure to support prescription fulfillment and cost management within state Medicaid and employee health plans.

Recent activity concentrates in Florida and Texas. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023 (note the date inconsistency in the source record). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities and market intelligence for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling state-level interest in restructuring pharmaceutical supply chains to bypass traditional pharmacy benefit managers and wholesalers. The RFI functions as exploratory procurement designed to inform future formal RFP strategy rather than a competitive bid round.